Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

206.64
+0.75000.36%
Post-market: 205.13-1.5124-0.73%16:53 EDT
Volume:1.57M
Turnover:324.32M
Market Cap:44.29B
PE:-23.16
High:208.82
Open:205.89
Low:204.07
Close:205.89
52wk High:224.31
52wk Low:45.72
Shares:214.34M
Float Shares:184.00M
Volume Ratio:0.78
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:16.99
PE(LYR):-34.73

Loading ...

Revolution Medicines Chief Development Officer Alan B. Sandler Disposes of USD 1,264,082 in Common Shares

Reuters
·
Yesterday

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Sells USD 743,436 in Common Shares

Reuters
·
Sep 29

Revolution Medicines Price Target Announced at $318.00/Share by Brookline Capital

Dow Jones
·
Sep 29

Buy Rating Reiterated on Revolution Medicines as KRAS G12D Lead Strengthens; $315 Price Target Maintained

TIPRANKS
·
Sep 29

Revolution Medicines Seen Having 'Strong' Rasonque Launch in Pancreatic Cancer, UBS Says

MT Newswires Live
·
Sep 28

Bernstein Sticks to Their Hold Rating for Revolution Medicines (RVMD)

TIPRANKS
·
Sep 26

Movement Alert|Revolution Medicines, Inc. Rises 5.06% in Regular Trading, Multiple Banks Raise Price Targets Amid FDA Breakthrough Therapy Designation

Market Focus
·
Sep 25

Revolution Medicines Director Elizabeth M. Anderson Disposes of $1,949,321.86 in Common Shares

Reuters
·
Sep 25

Movement Alert|Revolution Medicines, Inc. Rises 5.09% in Regular Trading, Multiple Banks Raise Price Targets Following FDA Breakthrough Therapy Designation

Market Focus
·
Sep 25

Revolution Medicines Price Target Announced at $267.00/Share by Goldman Sachs

Dow Jones
·
Sep 24

Revolution Medicines (RVMD) Gets a Buy from Goldman Sachs

TIPRANKS
·
Sep 24

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000

Reuters
·
Sep 23

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

GlobeNewswire
·
Sep 22

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

GlobeNewswire
·
Sep 22

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Reuters
·
Sep 22

Revolution Medicines Price Target Raised to $265.00/Share from $225.00 by B of a Securities

Dow Jones
·
Sep 22

BofA Securities Adjusts Revolution Medicines Price Target to $265 From $225, Maintains Buy Rating

MT Newswires Live
·
Sep 21

Revolution Medicines price target raised to $265 from $225 at BofA

TIPRANKS
·
Sep 21

Movement Alert|Revolution Medicines, Inc. Falls 5.1% in Regular Trading, Trading at $194.58

Market Focus
·
Sep 17

Revolution Medicines gets orphan designation for pancreatic cancer treatment

TIPRANKS
·
Sep 16